ERS Genomics and Syngulon Sign License Agreement on CRISPR-Cas9 Genome...

ERS Genomics Ltd and Syngulon, a synthetic biology startup developing original genetic technologies using bacteriocins, announced today a non-exclusive license agreement which provides Syngulon with...(PRWeb October 17, 2018)Read the full story at https://www.prweb.com/releases/ers_genomics_and_syngulon_sign_license_agreement_on_crispr_cas9_genome_editing_patents_for_industrial_applications/prweb15840777.htm

Source: PRWeb: Medical Pharmaceuticals - October 17, 2018 Category: Pharmaceuticals Source Type: news